Niels van de Roemer

Learn More
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the(More)
Multiple genetic events and subsequent clonal evolution drive carcinogenesis, making disease elimination with single-targeted drugs difficult. The multiplicity of gene mutations derived from clonal heterogeneity therefore represents an ideal setting for multiepitope tumor vaccination. Here, we used next generation sequencing exome resequencing to identify(More)
The 11th Annual Meeting of Association for Cancer Immunotherapy (CIMT) welcomed more than 700 scientists around the world to Mainz, Germany and continued to be the largest immunotherapy meeting in Europe. Renowned speakers from various fields of cancer immunotherapy gave lectures under CIMT2013's tag: "Advancing targeted therapies" the highlights of which(More)
In his opening lecture, Ira Mellman (Genentech, San Francisco, USA) introduced the current landscape of immunotherapeutic strategies comprising of checkpoint inhibitors, reversing tumor immunosuppression, vaccines and adoptive T cell therapies (ACT). He further underlined the need for biomarker profiling to guide immunotherapeuties against cancer which can(More)
The 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) brought together more than 800 scientists in Mainz, Germany, from May 11–13, 2015, to present and discuss current research on various fields of cancer immunotherapy. Special focus was set on personalized approaches, and independent of the specific therapeutic strategy, the(More)
More than 900 scientists around the world visited the 12th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in Mainz, Germany from 6–8 May, 2014. Recent advancements in various specific fields of cancer immunotherapy were discussed in Europe`s largest meeting of this kind under the motto “Next Waves in Cancer Immunotherapy,” the highlights(More)
Multiple genetic events and subsequent clonal evolution drive carcinogenesis, making disease eliminationwith single-targeted drugs difficult. The multiplicity of gene mutations derived from clonal heterogeneity therefore represents an ideal setting for multiepitope tumor vaccination. Here, we used next generation sequencing exome resequencing to identify(More)
  • 1